Merck Halts Mid-Stage Alzheimer's Drug Trial MK-1167 for Business Reasons
MRK sits 70% above its 52-week low of $76.66.
Summary
Merck has halted its mid-stage (Phase 2) trial for MK-1167, an Alzheimer's drug candidate, after enrolling approximately 350 patients. The study was closed in early June for "business reasons," not safety concerns. This is a pipeline setback in the high-value Alzheimer's therapeutic area, removing a potential future drug. The company's Q2 earnings call is scheduled for August 4th, where more details on this decision and its pipeline implications may be discussed.
At the time of this announcement, MRK was trading at $130.08 on NYSE in the Life Sciences sector, with a market capitalization of approximately $320B. The 52-week trading range was $76.66 to $130.29. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.